A PHASE 3, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 12 WEEKS OF SIMEPREVIR (SMV) PLUS SOFOSBUVIR (SOF) IN TREATMENT-NAIVE OR -EXPERIENCED PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION AND CIRRHOSIS: OPTIMIST-2